167 related articles for article (PubMed ID: 35813817)
1. Thioredoxin Reductase Inhibitors as Potential Antitumors: Mercury Compounds Efficacy in Glioma Cells.
Pires V; Bramatti I; Aschner M; Branco V; Carvalho C
Front Mol Biosci; 2022; 9():889971. PubMed ID: 35813817
[TBL] [Abstract][Full Text] [Related]
2. Exposure of human glioblastoma cells to thimerosal inhibits the thioredoxin system and decreases tumor growth-related factors.
Bramatti I; Aschner M; Branco V; Carvalho C
Toxicol Appl Pharmacol; 2024 Mar; 484():116844. PubMed ID: 38325586
[TBL] [Abstract][Full Text] [Related]
3. Toxicological effects of thiomersal and ethylmercury: Inhibition of the thioredoxin system and NADP(+)-dependent dehydrogenases of the pentose phosphate pathway.
Rodrigues J; Branco V; Lu J; Holmgren A; Carvalho C
Toxicol Appl Pharmacol; 2015 Aug; 286(3):216-23. PubMed ID: 25981166
[TBL] [Abstract][Full Text] [Related]
4. Impaired cross-talk between the thioredoxin and glutathione systems is related to ASK-1 mediated apoptosis in neuronal cells exposed to mercury.
Branco V; Coppo L; Solá S; Lu J; Rodrigues CMP; Holmgren A; Carvalho C
Redox Biol; 2017 Oct; 13():278-287. PubMed ID: 28600984
[TBL] [Abstract][Full Text] [Related]
5. Novel TrxR1 Inhibitors Show Potential for Glioma Treatment by Suppressing the Invasion and Sensitizing Glioma Cells to Chemotherapy.
Jovanović M; Dragoj M; Zhukovsky D; Dar'in D; Krasavin M; Pešić M; Podolski-Renić A
Front Mol Biosci; 2020; 7():586146. PubMed ID: 33134322
[TBL] [Abstract][Full Text] [Related]
6. Effects of Mammalian Thioredoxin Reductase Inhibitors.
Arnér ESJ
Handb Exp Pharmacol; 2021; 264():289-309. PubMed ID: 32767140
[TBL] [Abstract][Full Text] [Related]
7. Thimerosal, a competitive thioredoxin reductase 1 (TrxR1) inhibitor discovered via high-throughput screening.
Ni Y; Luo Z; Lv Y; Ma S; Luo C; Du D
Biochem Biophys Res Commun; 2023 Apr; 650():117-122. PubMed ID: 36780763
[TBL] [Abstract][Full Text] [Related]
8. The thioredoxin antioxidant system.
Lu J; Holmgren A
Free Radic Biol Med; 2014 Jan; 66():75-87. PubMed ID: 23899494
[TBL] [Abstract][Full Text] [Related]
9. Thioredoxin reductase: An emerging pharmacologic target for radiosensitization of cancer.
Patwardhan RS; Sharma D; Sandur SK
Transl Oncol; 2022 Mar; 17():101341. PubMed ID: 35078017
[TBL] [Abstract][Full Text] [Related]
10. A thioredoxin reductase and/or thioredoxin system-based mechanism for antioxidant effects of ambroxol.
Huang J; Xu J; Tian L; Zhong L
Biochimie; 2014 Feb; 97():92-103. PubMed ID: 24103200
[TBL] [Abstract][Full Text] [Related]
11. A systematic study of the disposition and metabolism of mercury species in mice after exposure to low levels of thimerosal (ethylmercury).
Carneiro MF; Oliveira Souza JM; Grotto D; Batista BL; de Oliveira Souza VC; Barbosa F
Environ Res; 2014 Oct; 134():218-27. PubMed ID: 25173055
[TBL] [Abstract][Full Text] [Related]
12. Pathogenic role of the SP/ NK1R system in GBM cells through inhibiting the thioredoxin system.
Ghahremani F; Sabbaghzadeh R; Ebrahimi S; Javid H; Ghahremani J; Hashemy SI
Iran J Basic Med Sci; 2021 Apr; 24(4):499-505. PubMed ID: 34094032
[TBL] [Abstract][Full Text] [Related]
13. The thioredoxin system as a target for mercury compounds.
Branco V; Carvalho C
Biochim Biophys Acta Gen Subj; 2019 Dec; 1863(12):129255. PubMed ID: 30447253
[TBL] [Abstract][Full Text] [Related]
14. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
15. Methyl and Ethylmercury elicit oxidative stress and unbalance the antioxidant system in Saccharomyces cerevisiae.
Ramos A; Dos Santos MM; de Macedo GT; Wildner G; Prestes AS; Masuda CA; Dalla Corte CL; Teixeira da Rocha JB; Barbosa NV
Chem Biol Interact; 2020 Jan; 315():108867. PubMed ID: 31672467
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents.
Liu Y; Li Y; Yu S; Zhao G
Curr Drug Targets; 2012 Oct; 13(11):1432-44. PubMed ID: 22876886
[TBL] [Abstract][Full Text] [Related]
17. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.
Tonissen KF; Di Trapani G
Mol Nutr Food Res; 2009 Jan; 53(1):87-103. PubMed ID: 18979503
[TBL] [Abstract][Full Text] [Related]
18. Thioredoxin System Protein Expression Is Associated with Poor Clinical Outcome in Adult and Paediatric Gliomas and Medulloblastomas.
Yao A; Storr SJ; Al-Hadyan K; Rahman R; Smith S; Grundy R; Paine S; Martin SG
Mol Neurobiol; 2020 Jul; 57(7):2889-2901. PubMed ID: 32418115
[TBL] [Abstract][Full Text] [Related]
19. High redox thioredoxin but low thioredoxin reductase activities in the serum of patients with rheumatoid arthritis.
Lemarechal H; Allanore Y; Chenevier-Gobeaux C; Ekindjian OG; Kahan A; Borderie D
Clin Chim Acta; 2006 May; 367(1-2):156-61. PubMed ID: 16458876
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial thioredoxin reductase inhibition, selenium status, and Nrf-2 activation are determinant factors modulating the toxicity of mercury compounds.
Branco V; Godinho-Santos A; Gonçalves J; Lu J; Holmgren A; Carvalho C
Free Radic Biol Med; 2014 Aug; 73():95-105. PubMed ID: 24816296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
